NICE rejects Novartis' migraine drug Aimovig, months after declining to endorse pricey Kymriah for adult use
Novartis $NVS is willing to play ball with UK’s cost-effectiveness watchdog NICE, who rejected their migraine prevention drug in a draft guidance on Thursday, months after declining to endorse the Swiss drugmaker’s cell therapy Kymriah in adult lymphoma patients.
The drug, erenumab, is sold as Aimovig in the United States by Novartis and partner Amgen $AMGN. It forms part of a new crop of biologics targeting the CGRP protein that transmits pain signals into the brain, and is considered instrumental in generating and maintaining headaches associated with migraine. Erenumab costs around £5,000 (about $6368) per year, excluding a confidential discount that would have been granted to England’s national health service (NHS) had NICE recommended the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.